ScienceDex / Researcher record
Baytop, Chanza
- Westat, Inc. (no department on record)
From the FY2022 NIH awards this investigator leads as contact PI. The department is the award's.
- Top 1% Funded
- Rising Star
NIH Funding · FY2022
Award-linked funding history
Linked NIH award amounts and rank by fiscal year.
View yearly values
| Fiscal year | Linked awards | Records | Rank |
|---|---|---|---|
| 2008 | $366,664 | 1 | #18,610 |
| 2022 | $30,462,382 | 1 | #45 |
| 2023 | $111,273,526 | 5 | #8 |
Award activity
Awards through the years
NIH award records listing this researcher in each fiscal year.
- FY20081 record
- FY2022 · selected1 record
- FY20235 records
Each bar starts at zero. Annual records can include renewals of the same project; they are not a count of distinct career grants.
Publications
Loading publications…
Researcher identity and coverage
- Current affiliation
- Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
- NIH RePORTER identity
- Profile ID unavailableSearch this ID in NIH RePORTER
- ORCID iD
- No ORCID iD on recordA researcher can add one by claiming this profile.
- ScienceDex PI coverage
- FY2008 through FY2023Career claims are limited to the years shown.Metrics use this researcher's latest loaded PI award year; ScienceDex is current through FY2026.
FY2022 award records by amount
NIH award records listing Baytop, Chanza as a PI. Multi-PI records show the full award amount for context.
- 3OT2HL158287-01S7OT2Contact PINHLBI Maternal Morbidity and Mortality (3M) Administrative Coordinating Center$30.5Maward amount
Award organization
Organizations that administered FY2022 awards listing Baytop, Chanza as a PI.
FY2022 award administered by Westat, Inc. (MD).
Coverage and award-record milestones
Computed from the fiscal years currently available in ScienceDex.
- 2008First NIH AwardWestat, Inc.
- 2022$500K Cumulative Funding
- 2022$1M Cumulative Funding
- 2022$2M Cumulative Funding
- 2022$5M Cumulative Funding
- 2022$10M Cumulative Funding
- 2022$25M Cumulative Funding
- 2022Entered Top 50% NationallyRanked #45
- 2022Entered Top 25% NationallyRanked #45
- 2022Entered Top 10% NationallyRanked #45
- 2022Entered Top 5% NationallyRanked #45
- 2022Entered Top 1% NationallyRanked #45
- 2023$50M Cumulative Funding
- 2023$100M Cumulative Funding